share_log

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

冠軍腫瘤學公司將於2022年9月8日星期四宣佈第一季度財務業績
Accesswire ·  2022/09/06 16:05

HACKENSACK, NJ / ACCESSWIRE / September 6, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 618777. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46511, or by accessing the investors section of the company's website within 72 hours.

新澤西州哈肯薩克/ACCESSWIRE/2022年9月6日/冠軍腫瘤公司(納斯達克代碼:CSBR)是一家全球領先的技術驅動的生物技術公司,正在通過創新的人工智能驅動的藥物-現象-多組學集成來改變藥物發現。該公司將於2022年9月8日(星期四)市場收盤後公佈截至2022年7月31日的第一季度財務和運營業績。該公司將於美國東部夏令時當天下午4:30(太平洋標準時間下午1:30)召開電話會議,討論結果。要加入呼叫,請撥打888-506-0062(國內)或973-528-0011(國際),並輸入接入碼618777。會議將通過撥打8774814010(國內)或919822331(國際)並輸入密碼46511或通過在72小時內訪問公司網站的投資者部分來重播。

About Champions Oncology, Inc.

冠軍腫瘤公司簡介

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit .

冠軍腫瘤是一家技術驅動的研究組織,開發針對癌症目標的創新療法,提供突破性的研究軟件作為服務,併為生物製藥組織提供端到端的研發服務。冠軍腫瘤學通過一種新的藥物-表觀-多組學整合方法積極參與藥物發現的轉變。欲瞭解更多信息,請訪問。

SOURCE: Champions Oncology, Inc.

資料來源:冠軍腫瘤學公司


View source version on accesswire.com:
在accesswire.com上查看源代碼版本:

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論